Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

12.5%

1 terminated/withdrawn out of 8 trials

Success Rate

87.5%

+1.0% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

3(37.5%)

Phase 1

2(25.0%)

Phase 4

1(12.5%)

Phase 3

1(12.5%)

N/A

1(12.5%)

8Total

Phase 2(3)

Phase 1(2)

Phase 4(1)

Phase 3(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04634539Phase 1Completed

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Role: collaborator

NCT05106101Phase 1Completed

L-glutamine Treatment in Patients With Diverticulosis

Role: lead

NCT04684381Phase 4Completed

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

Role: lead

NCT00586209Phase 2Terminated

L-Glutamine Therapy for Sickle Cell Anemia

Role: collaborator

NCT00125788Phase 2Completed

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Role: lead

NCT01179217Phase 3Completed

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Role: lead

NCT01576003Not ApplicableCompleted

Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants

Role: collaborator

NCT01051999Phase 2Completed

Glutamine Supplementation in Cystic Fibrosis

Role: collaborator

All 8 trials loaded